TBA-7371   Click here for help

GtoPdb Ligand ID: 13133

Synonyms: AZ-7371 | compound 1 [PMID:24957839] | TBA7371
Compound class: Synthetic organic
Comment: TBA-7371 was identified in a lead optimization study of a series of 1,4-azaindoles, a novel class of antibacterial compounds [1-3]. It has potent antimycobacterial activity and is under clinical evaluation as a treatment for tuberculosis (TB). TBA-7371 is a non-covalent inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 98.88
Molecular weight 355.39
XLogP -0.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CN=C2C(=CN(CC3=NC=NC(=C3C)OC)C2=C1)C(=O)NCCO
Isomeric SMILES CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
InChI InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
InChI Key VDRYGTNDKXIPSK-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
TBA-7371 has completed a Phase 2 trial to evaluate safety, pharmacokinetics, and early bactericidal activity (EBA) in adult participants with rifampicin-sensitive pulmonary tuberculosis (NCT04176250).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03199339 A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 Phase 1 Interventional Global Alliance for TB Drug Development
NCT04176250 Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis Phase 2 Interventional Bill & Melinda Gates Medical Research Institute